Clinical outcomes and costs of cardiothoracic surgery before and after the availability of aprotinin

Hospital Pharmacy

Volumn 32, Issue 2, 1997, Pages 203-209

  Sun, Grace R ^a,e   Chatton, Randy ^b   Lockwood, Allen ^c   Davies, Laurie K ^c,d  

^a Scientific Therapeutics Information Inc   (United States)

^b SHANDS Drug Information and Pharmacy Resource Center   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

aprotinin; blood products; coronary artery bypass surgery

Indexed keywords

APROTININ; FRESH FROZEN PLASMA;

ADULT; AGED; ANTICOAGULATION; BLEEDING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; DRUG COST; DRUG MARKETING; FEMALE; FIBRINOLYSIS; HUMAN; MALE; REVIEW; THORAX SURGERY; TREATMENT OUTCOME;

EID: 0031041745     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Aprotinin product information.Trasylol, West Haven, CT: Miles Inc.; 1994.
2. Taylor KM. Perioperative approaches to coagulation defects. Ann Thorac Surg. 1993;56:S78-S82.
3. Anon. Miles trasylol for coronary bypass blood-loss prevention/reduction "reserved for high risk patients," FDA suggests, protease inhibitor approved. FDC Reports: The Pink Sheet. 1994;56(1):6-7.
4. Lemmer JH, Stafford W, Bonney SL, et al. Aprotinin for coronary artery bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thor Cardiovasc Surg. 1994;107:543-553.
5. Anon. Aprotinin to reduce bleeding in cardiac surgery. Medical Lett Drugs Ther. 1994:36(924):50-51.
6. Harder MP, Leon E, Klaas JR, et al. Aprotinin reduces intraoperative blood and post-operative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg. 1991;51:936-941.
7. liu B, Belboul A, Al-Khaja N. High-dose aprotinin in reducing bleeding and protecting lung function in potential bleeders undergoing cardiopulmonary bypass. Chin Med J. 1991;104:980-985.
8. Havel M, Teufelsbauer H, Knobl P, et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thor Cardiovasc Surg. 1991;101:968-972.
9. Orchard MA, Goodchild CS, Prentice CRM, et al. Aprotinin reduces cardio-pulnionary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Hae,at. 1993;85:533-541.
10. Murkin JM, Lux J, Shannon NA, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg. 1994;107:554-561.
11. Bidstrup BP, Underwood SR, Sapsford RN. Effect of aprotinin or aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg. 1993;105:147-153.
12. Lathi KG, et al.Aprotinin cost effectiveness. Presented at the Society of Cardiovascular Anesthesiologists 1995 Annual Meeting. May 6-10,1995, Philadelphia, PA.
13. Bailey CR.Wielogorski AK. Randomized, placebo-controlled double-blind study of two low dose aprotinin regimens in cardiac surgery. Br Heart J. 1994;71:349-353.
14. Speekenbrink RGH, Wildevuur CRH, Sturk A, et al. Low-dose and high-dose aprotinin improve hemostasis in coronary operations. J Thorac Cardiovasc Surg. 1996;112:523-530.
15. Levy JH, Pifarre R, Schaff HV et al.A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirements for donor-blood transfusions in patients undergoing repeat coronary artery bypass grafting. Circulation. 1995;92:2236-2244.
16. Anon. Pharmacoeconomic data can be extrapolated to different settings in same manner as clinical data-PhRMA guidelines: Industry must avoid bias in PE studies. FDC Reports: ne Pink Sheet. 1995; 57(14):8-9.
17. Cooper BE. A perspective on aprotinin. Ann Pbannacother. 1996;30:407-408.
18. VandermeerJ.Hillege HL.Ascoop CAPL, et al. Aprotinin in aortocoronary bypasssurgery-increased risk of vein-graft occlusion and myocardial infarction: Supportive evidence from a retrospective study. Tbromb Haemostasis. 1996;75:1-3.
19. Laub GW, Riebman JB, Chen C, et al.The impact of aprotinin on coronary arter bypass graft patency. Chest. 1994;106:1370-1375.